Aardvark Therapeutics, Inc. Common Stock Working Capital to Net Assets Ratio

Latest as of September 2025: 96.8%

Aardvark Therapeutics, Inc. Common Stock working capital to net assets ratio. Aardvark Therapeutics, Inc. Common Stock (AARD) has a Working Capital to Net Assets ratio of 96.8% as of September 2025. Working capital of $118.47 Million (current assets of $129.21 Million minus current liabilities of $10.74 Million) is measured against net assets of $122.38 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Aardvark Therapeutics, Inc. Common Stock (AARD) tangible net worth to evaluate the tangible quality of the company's equity base.

WC/NA Ratio

96.8%
Working Capital / Net Assets

Working Capital

$118.47 Million
USD

Current Assets

$129.21 Million
USD

Current Liabilities

$10.74 Million
USD

Working Capital to Net Assets Ratio of Aardvark Therapeutics, Inc. Common Stock (2022–2024)

Working capital to net assets ratio of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. This chart shows how Aardvark Therapeutics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2022 to 2024. As of September 2025, the ratio stands at 96.8%, reflecting working capital of $118.47 Million against net assets of $122.38 Million USD. See AARD defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Aardvark Therapeutics, Inc. Common Stock Working Capital to Net Assets Ratio by Year (2022–2024)

Aardvark Therapeutics, Inc. Common Stock working capital to net assets ratio by year from 2022 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Aardvark Therapeutics, Inc. Common Stock.

Year WC/NA Ratio Working Capital (USD) Net Assets Current Assets Current Liabilities Change (pp)
2024 -126.7% $69.21 Million $-54.64 Million $74.14 Million $4.93 Million ▼ -100.8 pp
2023 -25.8% $8.99 Million $-34.80 Million $10.37 Million $1.38 Million ▲ +31.1 pp
2022 -56.9% $15.90 Million $-27.92 Million $16.49 Million $595.00K —
pp = percentage points